相关实验视频
Updated: Jul 17, 2025

05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
37.5K
血清素再吸收抑制剂与控制喘的关联
Alexander J Gajewski1, Jayme M Palka1, Josh M Raitt1
1From the Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, Texas.
Allergy and asthma proceedings
|August 29, 2023
概括
选择性血清素再吸收抑制剂 (SSRI) 和血清素和上腺素再吸收抑制剂 (SNRIs) 在没有抑郁症的患者中显著降低了喘恶化. 这包括更少的口服皮质类固醇处方,急诊室访问和住院治疗.
科学领域:
- 肺部医学 肺部医学
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 选择性血红素再吸收抑制剂 (SSRI) 改善了患有严重抑郁症 (MDD) 患者的喘控制.
- 这表明,在没有MDD的患者中,控制喘可能有好处.
- 氨酸和上腺素再吸收抑制剂 (SNRIs) 也调节与情绪和炎症相关的神经递质水平.
研究的目的:
- 调查SSRI和SNRIs对成人患者喘息控制的影响,这些患者没有被诊断出情绪障碍.
- 为了确定这些药物是否能减少这一群体中的喘恶化.
主要方法:
- 对592名患有喘和没有情绪障碍的成年患者的电子健康记录进行了回顾性分析.
- 在SSRI/SNRI开始前和之后的12个月内,比较口服皮质类固醇处方,急诊室 (ED) 访问和住院治疗.
- 利用威尔科克森签名的等级测试进行统计比较.
主要成果:
- SSRI/SNRI治疗与口服皮质类固醇使用的显著减少有关 (p = 0.003).
- 观察到与喘相关的ED访问显著减少 (p = 0.002).
- 由于喘而入院的病例也显著下降 (p < 0.001).
结论:
- 在没有伴随性抑郁症的患者中,SSRI/SNRI使用与严重喘恶化率的降低有关.
- 研究结果支持使用SSRI/SNRIs来改善除了患有MDD的患者之外的喘控制.
- 需要对前性,安慰剂对照研究进行进一步的研究,以证实在没有精神健康状况的喘患者中这些效应.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
270
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
270
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
433
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
433
Antiasthma Drugs: Leukotriene Modifiers
353
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
353
Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Antiasthma Drugs: β2-Adrenoceptor Agonists
298
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
298
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K

